Trends and Prospects of Stem Cell Research in China.
- Author:
Jing-Wen CAO
1
;
Lu ZHANG
2
;
Ye LI
3
;
Qing YANG
4
;
Wen-Hua FU
5
;
Xiao-Chen WANG
2
;
Wen-Long HUANG
4
Author Information
1. Shool of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, China; Office of Science and Technology Management, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
2. State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China.
3. Department of Science and Technology Management, National Health and Family Planning Commission of the People's Republic of China, Beijing 100044, China.
4. Shool of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, China.
5. Office of Science and Technology Management, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
- Publication Type:Journal Article
- From:
Chinese Medical Sciences Journal
2016;31(2):116-120
- CountryChina
- Language:English
-
Abstract:
Great progresses have been made in fundamental and clinical stem cell research in China in recent years. The official policy on stem cells, which was announced in 2015, seems as the spring of stem cell therapy in China. However, the regulation, governance, and management of clinical expectations are still challenging. This review summarized the current stem cell research and development in the field, as well as its rapidly evolving commercial, regulatory and ethical environment in China. As expected, the prospects of stem cells in China look prospective.
